Compare Crispr Therapeutics AG (CRSP) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kingsoft Cloud Holdings Limited — how do they compare? Crispr Therapeutics AG trades at $50.5 (market cap $4.97B), while Kingsoft Cloud Holdings Limited trades at $10.04 (market cap $2.93B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap. Which is the better fit depends on your goals.
| CRSP | KC | |
|---|---|---|
Market Cap | $4.97B | $2.93B |
Sector | Health | Technology |
52-Week High | $76.78 | $18.21 |
52-Week Low | $44.34 | $8.58 |
Enterprise Value | $3.32B | $3.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Kingsoft Cloud (KC) trades at $10.39, down 4.77% today, with a bullish technical signal and strong analyst support (70% buy ratings). Recent quarters show consistent earnings beats, though the company remains unprofitable with a -9.39% net margin. Revenue growth is robust, driven by AI cloud demand, while cash flow from operations improved to $3.80B in 2025. Technical indicators suggest bullish momentum with support near $10 and resistance at $11.
The stock presents a growth opportunity amid China's AI expansion, but profitability challenges and high valuation multiples pose risks. Analyst consensus points to 25.4% upside potential, though execution on margin improvement is critical for sustained gains. Macroeconomic and regulatory factors in China remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
